Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Anal cancer is an uncommon type of cancer, which begins around or just inside the anal opening. Anal cancer can be classified into different types such as carcinoma in-situ, squamous cell carcinoma, melanoma, adenocarcinoma, and basal cell carcinoma. Carcinoma in-situ refers to stage zero anal cancer wherein the cancerous cells remain only at the site of its origin and does not spread to other parts of the body. Anal canal is lined by flat squamous cells and when these cells turn cancerous it gives rise to squamous cell carcinoma, which is the most common type of anal cancer. Melanoma begins in the cells responsible for production of color of skin or anal lining. Adenocarcinoma begins in the mucous production glands present under the anal lining. Basal cell carcinoma occurs in the perianal skin (around the anus). Some of the common symptoms that appear if one has anal cancer include swelling of anus, bleeding in the anus, and discharge from the anus, irregular bowel movements, and others. Anal cancer can be treated using chemotherapy, surgery, immunotherapy, and radiation therapy.
The global anal cancer market is estimated to be valued at US$ 810.4 million in 2021 and is expected to exhibit a CAGR of 6.3% over the forecast period (2021-2028).
Figure 1. Global Anal Cancer Market Share (%), By Region, 2021
The increasing incidence of anal cancer and sexually transmitted diseases is expected to drive the growth of the global anal cancer market over the forecast period.
For instance, according to data published by the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program, U.S, it is estimated that the rate of new cases of anal cancer has increased from 1.7 per 100,000 persons in 2008 to 1.8 per 100,000 persons in 2018 and is expected to increase following the same trend in near future.
Figure 2. Global Anal Cancer Market Share (%), By Treatment Type, 2021
The increasing research and development activities for the development of novel therapeutics for the treatment of anal cancer is expected to drive the market growth over the forecast period.
Key players operating in the market are focusing on research and development activities for treatment of anal cancer, which is expected to drive growth of the global anal cancer market over the forecast period.
For instance, in October 2016, Dana-Farber Cancer Institute, Massachusetts and Merck Sharp & Dohme Corp., a U.S. based pharmaceutical company initiated a phase II clinical trial study for assessing the potential use of Pembrolizumab, a monoclonal antibody drug manufactured by Merck Sharp & Dohme Corp. for treatment of advanced anal cancer. This phase II clinical study is expected to be completed by March 2023.
Anal Cancer Market Report Coverage
||Market Size in 2021:
||US$ 810.4 Mn
|Historical Data for:
||2017 to 2020
||2021 to 2028
|Forecast Period 2021 to 2028 CAGR:
||2028 Value Projection:
||US$ 1,242.9 Mn
- North America: U.S. and Canada
- Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
- Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
- Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
- Middle East: GCC Countries, Israel, and Rest of Middle East
- Africa: South Africa, North Africa, and Central Africa
- By Drug Type: Fluorouracil, Cisplatin, Carboplatin, Others (Others include Mitomycin, Oxaliplatin, Docetaxel, Leucovorin, etc.)
- By Cancer Type: Carcinoma In-situ, Squamous Cell Carcinoma, Melanoma, Adenocarcinoma, Basal Cell Carcinoma
- By Treatment Type: Chemotherapy, Surgery, Radiation Therapy, Immunotherapy
- By Distribution Channel: Hospitals & Clinics, Research & Academic Institutes, Long-term Care Centers, Pharmacies
||Advaxis, Inc., ORYX GmbH and Co. KG, Eli Lilly and Company, Merck KGaA, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Onconova Therapeutics, BioMimetix JV, LLC, Bayer AG, Spectrum Pharmaceuticals Inc., Global BioPharma Inc., Amgen Inc., Atara Biotherapeutics Inc., ISA Pharmaceuticals, Takeda Pharmaceutical Company Limited, Ono Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, Novartis AG, Pfizer Inc., Sanofi, and Johnson & Johnson Private Limited
- Increasing prevalence of sexually transmitted diseases and anal cancer
- Growing research and development activities by market players for anal cancer treatment
|Restraints & Challenges:
- Side effects of chemotherapy drugs used for anal cancer treatment
Global Anal Cancer Market – Impact of Coronavirus (Covid-19) Pandemic
Coronavirus (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19, as pandemic on March 11, 2020. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 231,416,660 cases and 4,741,330 deaths due to coronavirus (COVID-19) were reported till September 26, 2021, across the globe.
The COVID-19 pandemic and lockdown in various countries across the globe has negatively impacted the financial status of businesses across all sectors. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry mainly due to strict lockdown in several regions. Likewise, COVID-19 pandemic is expected to have a negative impact on the global anal cancer market due to financial challenges faced by hospitals and healthcare facilities during pandemic. For instance, according to an article published by the Elsevier Public Health Emergency Collection journal in November 2020, it is estimated that hospitals and healthcare systems in the U.S. are subjected to a financial impact of US$ 202.6 billion in lost revenue during the pandemic.
Global Anal Cancer Market Restraint
The side effects of chemotherapy drugs used in the treatment of anal cancer are the factors that are expected to hinder growth of the global anal cancer market over the forecast period. For instance, according to an article published by the American cancer Society in November 2017, some of the side effects associated with use of chemotherapy drugs in the treatment of anal cancer include nausea, vomiting, loss of appetite, hair loss, diarrhea, mouth sores, and others.
Major players operating in the global anal cancer market include Advaxis, Inc., ORYX GmbH and Co. KG, Eli Lilly and Company, Merck KGaA, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Onconova Therapeutics, BioMimetix JV, LLC, Bayer AG, Spectrum Pharmaceuticals Inc., Global BioPharma Inc., Amgen Inc., Atara Biotherapeutics Inc., ISA Pharmaceuticals, Takeda Pharmaceutical Company Limited, Ono Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, Novartis AG, Pfizer Inc., Sanofi, and Johnson & Johnson Private Limited